Which region held the largest market share in the CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market market?

North America is the region to held the largest market share with 57% growth. Read More

Which Segment has the largest market share in the CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market market?

Type is the segment that has the largest market share in the market. Read More

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Q: How much is the CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market market?

The ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market market size is estimated to grow at $$ 2230 mn in 2023. Read More

Q: What is the growth rate of the CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market market?

The growth rate of the ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market year-over-year is 15.11%. Read More

Q: Who are the key players in the CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market market?

AstraZeneca Plc, Bio Techne Corp., BioNTech SE, Bristol Myers Squibb Co., HBM Holdings Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Ono Pharmaceutical .... Read More

Published: Dec 2023
Pages: 163
SKU: IRTNTR72722

Enjoy complimentary customisation on priority with our Enterprise License!

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market 2024-2028

The CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market size is estimated to grow by USD 2,230 million at a CAGR of 15.11% between 2023 and 2028.

Strategic alliances for collaboration and licensing are expected to help co-develop and commercialize CTLA4 inhibitors globally. Co-development agreements empower the use of technical expertise from both companies, which would help them promote and support each other to develop CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors market novel drugs. Currently, the drug development is being reported by AstraZeneca and is being tested in phase III clinical trials as a combination drug for treating various cancers. Such strategic alliances and collaborations help companies in geographical expansion and accelerating the development of new drugs with significant investments. The products that are co-developed and marketed through alliances enable companies to gain high ROI. Hence, such strategic alliances are expected to drive the market's growth during the forecast period.

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market 2018 - 2022 ($ million)

4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)

4.3 Distribution Channel Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Monotherapy - Market size and forecast 2023-2028
- Exhibit 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)

6.4 Combination therapy - Market size and forecast 2023-2028
- Exhibit 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)
- Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)

7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel

7.3 Hospital pharmacies - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)

7.4 Retail pharmacies - Market size and forecast 2023-2028
- Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)

7.5 Online pharmacies - Market size and forecast 2023-2028
- Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ million)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Germany - Market size and forecast 2023-2028
- Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.9 Canada - Market size and forecast 2023-2028
- Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 Agenus Inc.
- Exhibit 111: Agenus Inc. - Overview
- Exhibit 112: Agenus Inc. - Product / Service
- Exhibit 113: Agenus Inc. - Key offerings

12.4 Akeso Inc.
- Exhibit 114: Akeso Inc. - Overview
- Exhibit 115: Akeso Inc. - Product / Service
- Exhibit 116: Akeso Inc. - Key offerings

12.5 AstraZeneca Plc
- Exhibit 117: AstraZeneca Plc - Overview
- Exhibit 118: AstraZeneca Plc - Product / Service
- Exhibit 119: AstraZeneca Plc - Key news
- Exhibit 120: AstraZeneca Plc - Key offerings

12.6 Bio Techne Corp.
- Exhibit 121: Bio Techne Corp. - Overview
- Exhibit 122: Bio Techne Corp. - Business segments
- Exhibit 123: Bio Techne Corp. - Key offerings
- Exhibit 124: Bio Techne Corp. - Segment focus

12.7 BioNTech SE
- Exhibit 125: BioNTech SE - Overview
- Exhibit 126: BioNTech SE - Key offerings

12.8 Bristol Myers Squibb Co.
- Exhibit 127: Bristol Myers Squibb Co. - Overview
- Exhibit 128: Bristol Myers Squibb Co. - Product / Service
- Exhibit 129: Bristol Myers Squibb Co. - Key news
- Exhibit 130: Bristol Myers Squibb Co. - Key offerings

12.9 HBM Holdings Ltd.
- Exhibit 131: HBM Holdings Ltd. - Overview
- Exhibit 132: HBM Holdings Ltd. - Product / Service
- Exhibit 133: HBM Holdings Ltd. - Key offerings

12.10 Innovent Biologics Inc.
- Exhibit 134: Innovent Biologics Inc. - Overview
- Exhibit 135: Innovent Biologics Inc. - Product / Service
- Exhibit 136: Innovent Biologics Inc. - Key offerings

12.11 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Exhibit 137: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
- Exhibit 138: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
- Exhibit 139: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings

12.12 Merck and Co. Inc.
- Exhibit 140: Merck and Co. Inc. - Overview
- Exhibit 141: Merck and Co. Inc. - Business segments
- Exhibit 142: Merck and Co. Inc. - Key news
- Exhibit 143: Merck and Co. Inc. - Key offerings
- Exhibit 144: Merck and Co. Inc. - Segment focus

12.13 Ono Pharmaceutical Co. Ltd.
- Exhibit 145: Ono Pharmaceutical Co. Ltd. - Overview
- Exhibit 146: Ono Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 147: Ono Pharmaceutical Co. Ltd. - Key offerings

12.14 Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Exhibit 148: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Overview
- Exhibit 149: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Business segments
- Exhibit 150: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Key offerings
- Exhibit 151: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Segment focus

12.15 TRACON Pharmaceuticals Inc.
- Exhibit 152: TRACON Pharmaceuticals Inc. - Overview
- Exhibit 153: TRACON Pharmaceuticals Inc. - Product / Service
- Exhibit 154: TRACON Pharmaceuticals Inc. - Key offerings

12.16 Xencor Inc.
- Exhibit 155: Xencor Inc. - Overview
- Exhibit 156: Xencor Inc. - Product / Service
- Exhibit 157: Xencor Inc. - Key news
- Exhibit 158: Xencor Inc. - Key offerings

12.17 XILIO THERAPEUTICS INC.
- Exhibit 159: XILIO THERAPEUTICS INC. - Overview
- Exhibit 160: XILIO THERAPEUTICS INC. - Product / Service
- Exhibit 161: XILIO THERAPEUTICS INC. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 162: Inclusions checklist
- Exhibit 163: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 164: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 165: Research methodology
- Exhibit 166: Validation techniques employed for market sizing
- Exhibit 167: Information sources